AGP Executive Report
Last update: 9 hours agoSwiss Pharma Watch: Novartis reported higher-than-expected Q2 core operating income, with newer medicines helping offset Entresto’s slide as generics bite, and it kept its 2026 outlook. Cancer Tech & IP: The European Patent Office upheld patent protection for SOTIO’s PD-1 immunocytokine SOT201, strengthening its IP position for early-stage cancer work. Cardiology Devices: Vesalio’s randomized NATURE trial of its enVast coronary thrombectomy system was selected for a late-breaking presentation at the ESC Congress in Munich. Biotech Deals: Lonza and Engitix signed a licensing agreement to advance ADC development, while Immitra raised CHF 2.4M to push in-vivo gene editing toward an inherited anemia approach. Public Health & Prevention: India approved its first dengue vaccine, Qdenga, for ages 4–60, marking a major step in dengue prevention. Environment & Health Risks (Switzerland): A Swiss study links rising calima dust events to climate change, and separate reporting says Japanese beetles are spreading to more Swiss regions—prompting new local control measures. Wellness in Zurich: Swissline opened the renovated Labo Spa flagship in Zurich, positioning it as “Swiss” skincare plus hospitality.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
![[Latest] Pharma 4.0 Market Size Expected to Reach USD 90.71 Billion by 2034, With 19.80% CAGR; Digital Transformation Initiatives, Regulatory Data Integrity Mandates, and Smart Manufacturing Needs to Propel Market Growth](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/18574987-652842201-zion-market-research-jpg-100x100.jpeg)
